J Korean Med Sci.
2021 Jun;36(22):e167. 10.3346/jkms.2021.36.e167.
Letter to the Editor: How Should We Treat High-risk Patients in the Chronic Phase Following PCI: Clopidogrel or Prolonged DAPT?
- Affiliations
-
- 1Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- KMID: 2516585
- DOI: http://doi.org/10.3346/jkms.2021.36.e167
Reference
-
1. Kim DY, Cho SW, Park KT, Ahn JH, Park TK, Jang YH, et al. Long-term outcomes of clopidogrel monotherapy versus prolonged dual antiplatelet therapy beyond 12 months after percutaneous coronary intervention in high-risk patients. J Korean Med Sci. 2021; 36(16):e106. PMID: 33904262.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Long-term Outcomes of Clopidogrel Monotherapy versus Prolonged Dual Antiplatelet Therapy beyond 12 Months after Percutaneous Coronary Intervention in High-risk Patients
- Stent thrombosis and optimal duration of dual antiplatelet therapy after coronary stenting in contemporary practice
- Clinical significance of high on-treatment platelet reactivity in patients with prolonged clopidogrel therapy
- The Efficacy of P2Y12 Reactive Unit to Predict the Periprocedural Thromboembolic and Hemorrhagic Complications According to Clopidogrel Responsiveness and Safety of Modification of Dual Antiplatelet Therapy : A Meta-Analysis
- Assessment of Clinical Outcomes of Dual Antiplatelet Therapy in Elderly Patients with Percutaneous Coronary Intervention
